文献速递肺栓塞与肺血管病

慢性血栓栓塞性肺动脉高压的评估与管理

Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension.
PubMed 文献 · Chest · 2023-03-28

慢性血栓栓塞性肺动脉高压(CTEPH)是急性肺栓塞后血栓未完全溶解导致的第4组肺动脉高压,约3%急性肺栓塞后发生。V/Q显像是最佳筛查方法,肺血管造影和右心导管用于确诊。肺动脉血栓内膜剥脱术可使部分患者治愈(专家中心死亡率约2%),但超过三分之一患者无法手术,可用药物和球囊肺动脉成形术治疗。

要点

  • 所有疑似肺动脉高压患者均应考虑CTEPH诊断,即使无VTE病史。
  • V/Q显像为最佳筛查试验,确诊需肺血管造影和右心导管。
  • 治疗应由多学科团队评估,手术与药物/球囊成形术个体化选择。

核心结论

  • CTEPH是可治疗的肺动脉高压和右心衰竭形式,手术与介入/药物治疗可改善可手术和不可手术患者的结局。

研究设计与样本

  • 综述,总结CTEPH的评估与管理,未报告系统检索范围或样本量。

主要发现

  • CTEPH真实发病率不明确,估计急性肺栓塞后约3%。
  • V/Q显像为最佳筛查试验,CT和其他先进影像在检测和确认中作用增大。
  • 专家中心肺动脉血栓内膜剥脱术死亡率约2%,手术技术进步使更远端内膜剥脱成功且结局良好。
  • 超过三分之一患者可能被认为无法手术。

关键数值与推荐

  • 肺动脉高压背景下V/Q显像灌注缺损提示CTEPH,但确诊和治疗规划需肺血管造影和右心导管。
  • 所有疑似肺动脉高压患者均应考虑CTEPH诊断。
  • 治疗应基于多学科团队评估个体化制定。

临床怎么用

  • 对疑似肺动脉高压患者应筛查CTEPH,V/Q显像阴性可基本排除。
  • 确诊后经多学科团队评估选择手术、球囊肺动脉成形术或药物治疗。

局限性

  • CTEPH真实发病率不明确。
  • 综述未报告系统检索范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic thromboembolic pulmonary hypertension (CTEPH) is a treatable form of pulmonary hypertension and right heart failure. CTEPH (group 4 pulmonary hypertension) is caused by persistent organized thromboembolic obstruction of the pulmonary arteries from incompletely resolved acute pulmonary embolism. CTEPH also may present without prior VTE history, which can contribute to its underrecognition. The true incidence of CTEPH is unclear, but is estimated to be approximately 3% after acute pulmonary embolism. V˙/Q˙ scintigraphy is the best screening test for CTEPH, with CT scan imaging and other advanced imaging methods now playing a larger role in disease detection and confirmation. Perfusion defects on V˙/Q˙ scintigraphy in the setting of pulmonary hypertension are suggestive of CTEPH, but pulmonary angiography and right heart catheterization are required for confirmation and treatment planning. CTEPH potentially is curative with pulmonary thromboendarterectomy surgery, with mortality rates of approximately 2% at expert centers. Advances in operative techniques are allowing more distal endarterectomies to be performed successfully with favorable outcomes. However, more than one-third of patients may be considered inoperable. Although these patients previously had minimal therapeutic options, effective treatments now are available with pharmacotherapy and balloon pulmonary angioplasty. Diagnosis of CTEPH should be considered in all patients with suspicion of pulmonary hypertension. Treatments for CTEPH have advanced with improvements in outcomes for both operable and inoperable patients. Therapy should be tailored based on multidisciplinary team evaluation to ensure optimal treatment response.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Yang J, Madani MM, Mahmud E, et al. Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension. Chest. 2023. PMID: 36990148. doi:10.1016/j.chest.2023.03.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。